Summary: A new randomized, double-blind, placebo-controlled crossover study has found that suvorexant, an orexin receptor antagonist approved for treating insomnia, promotes fat oxidation and reduces protein catabolism during sleep without significantly changing total sleep time. … [Read more...]
FDA Rejects Petition Challenging Safety of Narcolepsy Drug Wakix
Summary: The FDA has denied a citizen petition filed by a short seller challenging the safety and effectiveness of Wakix (pitolisant) for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy. The FDA reaffirmed Wakix’s favorable benefit-risk profile and … [Read more...]
FDA Approves Non-Scheduled Narcolepsy Drug for Children
Summary: The FDA has expanded the approval of a narcolepsy drug, previously approved for adults, to now include children aged 6 and older. This new approval provides a non-scheduled treatment option for pediatric patients experiencing excessive daytime sleepiness due to … [Read more...]
Diabetes Drug Shows Potential as Sleep Apnea Treatment
Summary: New evidence published in the New England Journal of Medicine demonstrates that tirzepatide, a drug developed for diabetes, significantly reduces the severity of obstructive sleep apnea (OSA) in patients with obesity. Conducted by researchers at the University of … [Read more...]
Drug Candidate Shows Sleep, RLS Benefits in Parkinson’s Patients
Summary: New data from a period 2A research presented at the XXIX Environment Congress implies that BioVie Inc’s investigational drug bezisterim may greatly enhance rest, reduce tiredness, and ease restless leg signs or symptoms in Parkinson’s condition people when used with … [Read more...]
Apnimed Completes Enrollment for Phase 3 Sleep Apnea Drug Trial
Summary: Apnimed, a medical-stage pharmaceutical enterprise, has done early enrollment for its LunAIRo stage 3 research, assessing the efficacy and safety of its direct candidate Advert109 for managing obstructive sleep apnea (OSA). Advertisement109, a probable very first oral … [Read more...]
FDA OKs Phase 1 Trial of Narcolepsy Drug Candidate ORX750
Summary: Centessa Prescription drugs has received Food and drug administration authorization to commence a section 1 demo of ORX750, an investigational oral therapy aimed at narcolepsy and other slumber-wake conditions. ORX750, a selective orexin receptor 2 agonist, addresses the … [Read more...]
Eli Lilly’s Weight Loss Drug Zepbound Cuts Sleep Apnea Severity
Summary: Eli Lilly announced that its weight-loss drug Zepbound (tirzepatide) reduced the severity of obstructive sleep apnea (OSA) by up to 63% in adults with obesity in two phase 3 trials. The drug improved sleep apnea symptoms in patients using and not using PAP therapy. Based … [Read more...]
Incannex CEO: ‘Remarkable’ Results Drive Sleep Apnea Drug Trial
Summary: Incannex Health care Inc furnished an update on its stage 2/3 trials of IHL-42X, its drug candidate becoming formulated for the procedure of obstructive rest apnea (OSA), detailing preparation throughout 25 US web sites with growth plans into Europe. This proprietary … [Read more...]
Zevra Highlights Plans to Advance IH, Narcolepsy Drug Candidate
Summary: Zevra Therapeutics Inc., in its yr-conclude fiscal and corporate update for 2023, highlighted the development of KP1077 in dealing with idiopathic hypersomnia, citing promising Stage 2 analyze final results. The organization also introduced designs to existing new info … [Read more...]